Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Buy” from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $196.75.

Several equities research analysts recently weighed in on KRYS shares. Stifel Nicolaus increased their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Citigroup restated a “neutral” rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Finally, HC Wainwright upped their price target on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Krystal Biotech by 1.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC boosted its stake in Krystal Biotech by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Krystal Biotech by 23.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock valued at $28,292,000 after purchasing an additional 43,709 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.3 %

KRYS opened at $174.98 on Friday. The stock has a 50-day moving average price of $185.63 and a 200-day moving average price of $179.97. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The stock has a market capitalization of $5.00 billion, a P/E ratio of 93.57 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s quarterly revenue was up 70283900.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) EPS. On average, equities research analysts predict that Krystal Biotech will post 3.13 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).